Document Classification

Section Type: RESULTS

Text: In the modified intent-to-treat analysis (randomized patients who received at least 1 dose) there was no significant difference in the primary end point of 28-day all-cause mortality with 28. 1 % (366/1304) in the eritoran group vs 26. 9 % (177/657) in the placebo group (P =. 59 ; hazard ratio, 1. 05 ; 95 % CI, 0. 88-1. 26 ; difference in mortality rate, -1. 1 ; 95 % CI, -5. 3 to 3. 1) or in the key secondary end point of 1-year all-cause mortality with 44. 1 % (290/657) in the eritoran group vs 43. 3 % (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P =. 79 (hazard ratio, 0. 98 ; 0. 85-1. 13).